National Cancer Institute (NCI): Central Nervous System Neoplasms trials

The registry lists 50 Central Nervous System Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 1 27Phase 2 22No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingNCT03598244Phase 1Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213691Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsCompletedNCT02780804Phase 1Results posted
• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent MalignanciesCompletedNCT02116777Phase 1/2Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior BevacizumabCompletedNCT01931098Phase 2Results posted
• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsCompletedNCT01709435Phase 1Results posted
• Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal TumorsCompletedNCT01217437Phase 2Results posted
• O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation TherapyTerminatedNCT00436436Phase 2Results posted
• O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem TumorsCompletedNCT00275002Phase 2Results posted
• Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent GliomaTerminatedNCT00021229Phase 1/2Results posted
• Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) TumorsCompletedNCT07374692
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
• Rare CNS Tumors Outcomes &RiskCompletedNCT03251989
• Biomarker Analysis of Central Nervous System TumorsTerminatedNCT02692898
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1
• Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System TumorsCompletedNCT01538095Phase 1
• Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System TumorsCompletedNCT01445288
• Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous SystemCompletedNCT00867178Phase 1
• Lapatinib in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00099060Phase 1/2
• Alanosine in Treating Patients With Progressive or Recurrent Malignant GliomasCompletedNCT00075894Phase 1
• CC-8490 in Treating Patients With Recurrent or Refractory High-Grade GliomasCompletedNCT00074243Phase 1
• Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00053183Phase 1
• Brachytherapy in Treating Patients With Recurrent Malignant GliomaCompletedNCT00045474Phase 1
• CC-5013 in Treating Patients With Recurrent GliomaCompletedNCT00036894Phase 1
• Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research ProtocolsTerminatedNCT00035373
• Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the BrainCompletedNCT00032097Phase 1
• Mafosfamide in Treating Patients With Progressive or Refractory Meningeal TumorsCompletedNCT00031928Phase 1
• Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsCompletedNCT00020150Phase 1
• Lobradimil and Carboplatin in Treating Children With Brain TumorsCompletedNCT00019422Phase 2
• Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant GliomaCompletedNCT00019071Phase 1
• Radiation Therapy in Treating Patients With GlioblastomaCompletedNCT00019058Phase 1
• Atrasentan in Treating Patients With Progressive or Recurrent Malignant GliomaCompletedNCT00017264Phase 1
• Karenitecin in Treating Patients With Recurrent Malignant GliomaCompletedNCT00014521Phase 1
• Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00006102Phase 2
• Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent GliomaCompletedNCT00005976Phase 2
• O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant GliomaCompletedNCT00004892Phase 1
• Gene Therapy in Treating Patients With Recurrent or Progressive Brain TumorsCompletedNCT00004080Phase 1
• Carmustine in Treating Patients With Recurrent Malignant GliomaCompletedNCT00004028Phase 1
• O6-benzylguanine and Carmustine in Treating Children With Refractory CNS TumorsCompletedNCT00003765Phase 1
• Docetaxel in Treating Children With Recurrent Solid TumorsCompletedNCT00002825Phase 2